Targeting p53 mutant ovarian cancer: Phase I results of the WEE1 inhibitor MK-1775 with carboplatin plus paclitaxel in patients (pts) with platinum-sensitive, p53-mutant ovarian cancer (OC).
Irene Brana
No relevant relationships to disclose
Kathleen N. Moore
No relevant relationships to disclose
Ronnie Shapira-Frommer
No relevant relationships to disclose
Stephen Welch
Research Funding - Amgen; Merck; Roche
Ying-Ming Jou
Employment or Leadership Position - Merck
Stock Ownership - Merck
Michelle Marinucci
Employment or Leadership Position - Merck
Tomoko Freshwater
Employment or Leadership Position - Merck
Shelonitda Rose
Employment or Leadership Position - Merck
Stock Ownership - Merck
Amit M. Oza
No relevant relationships to disclose